Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Interfacial pH Behavior at a Cell/Gate Insulator Nanogap Induced by Allergic Responses.

Satake H, Sakata T.

ACS Omega. 2019 Aug 22;4(10):14255-14260. doi: 10.1021/acsomega.9b01872. eCollection 2019 Sep 3.

2.

Identification of a New Theca/Interstitial Cell-Specific Gene and Its Biological Role in Growth of Mouse Ovarian Follicles at the Gonadotropin-Independent Stage.

Aoyama M, Shiraishi A, Matsubara S, Horie K, Osugi T, Kawada T, Yasuda K, Satake H.

Front Endocrinol (Lausanne). 2019 Aug 14;10:553. doi: 10.3389/fendo.2019.00553. eCollection 2019.

3.

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.

Munemoto Y, Nakamura M, Takahashi M, Kotaka M, Kuroda H, Kato T, Minagawa N, Noura S, Fukunaga M, Kuramochi H, Touyama T, Takahashi T, Miwa K, Satake H, Kurosawa S, Miura T, Mishima H, Sakamoto J, Oba K, Nagata N.

Eur J Cancer. 2019 Aug 21;119:158-167. doi: 10.1016/j.ejca.2019.07.006. [Epub ahead of print]

4.

Synthesis of Uracil-Iodonium(III) Salts for Practical Utilization as Nucleobase Synthetic Modules.

Takenaga N, Hayashi T, Ueda S, Satake H, Yamada Y, Kodama T, Dohi AT.

Molecules. 2019 Aug 21;24(17). pii: E3034. doi: 10.3390/molecules24173034.

5.

Reduction and Escalation in the Dose of Sunitinib were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine: A Case Report.

Ogata M, Satake H, Ogata T, Hatachi Y, Hara S, Hirota S, Yasui H.

Intern Med. 2019 Jul 22. doi: 10.2169/internalmedicine.2806-19. [Epub ahead of print]

6.

Identification of a binding protein for sesamin and characterization of its roles in plant growth.

Tera M, Koyama T, Murata J, Furukawa A, Mori S, Azuma T, Watanabe T, Hori K, Okazawa A, Kabe Y, Suematsu M, Satake H, Ono E, Horikawa M.

Sci Rep. 2019 Jun 14;9(1):8631. doi: 10.1038/s41598-019-45003-7.

7.

Functional characterization of an invertebrate gonadotropin-releasing hormone receptor in the Yesso scallop Mizuhopecten yessoensis.

Nagasawa K, Matsubara S, Satake H, Osada M.

Gen Comp Endocrinol. 2019 Oct 1;282:113201. doi: 10.1016/j.ygcen.2019.06.005. Epub 2019 Jun 11.

PMID:
31199924
8.

Different characteristics of postoperative atrial tachyarrhythmias between congenital and non-congenital heart disease.

Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Satake H, Segawa M, Hirano M, Shimokawa H.

J Interv Card Electrophysiol. 2019 Jun 13. doi: 10.1007/s10840-019-00575-2. [Epub ahead of print]

PMID:
31197584
9.

Peptide receptors and immune-related proteins expressed in the digestive system of a urochordate, Ciona intestinalis.

Satake H, Matsubara S, Shiraishi A, Yamamoto T, Osugi T, Sakai T, Kawada T.

Cell Tissue Res. 2019 Sep;377(3):293-308. doi: 10.1007/s00441-019-03024-8. Epub 2019 May 11. Review.

PMID:
31079207
10.

Characteristics of ventricular tachycardia and long-term treatment outcome in patients with dilated cardiomyopathy complicated by lamin A/C gene mutations.

Hasebe Y, Fukuda K, Nakano M, Kumagai K, Karibe A, Fujishima F, Satake H, Kondo M, Wakayama Y, Shimokawa H.

J Cardiol. 2019 May 3. pii: S0914-5087(19)30101-7. doi: 10.1016/j.jjcc.2019.03.019. [Epub ahead of print]

PMID:
31060954
11.

Repertoires of G protein-coupled receptors for Ciona-specific neuropeptides.

Shiraishi A, Okuda T, Miyasaka N, Osugi T, Okuno Y, Inoue J, Satake H.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7847-7856. doi: 10.1073/pnas.1816640116. Epub 2019 Apr 1.

12.

Monitoring of fatigue in radiologists during prolonged image interpretation using fNIRS.

Nihashi T, Ishigaki T, Satake H, Ito S, Kaii O, Mori Y, Shimamoto K, Fukushima H, Suzuki K, Umakoshi H, Ohashi M, Kawaguchi F, Naganawa S.

Jpn J Radiol. 2019 Jun;37(6):437-448. doi: 10.1007/s11604-019-00826-2. Epub 2019 Mar 19.

PMID:
30891667
13.

Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.

Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, Hashida H, Hamada M, Yasui H.

Oncotarget. 2019 Feb 1;10(10):1070-1084. doi: 10.18632/oncotarget.26626. eCollection 2019 Feb 1.

14.

Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.

Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H.

Int J Clin Oncol. 2019 Jul;24(7):836-841. doi: 10.1007/s10147-019-01414-0. Epub 2019 Feb 18.

PMID:
30778794
15.

Ultraviolet B-induced Otx2 expression in lens epithelial cells promotes epithelial-mesenchymal transition.

Yoshitomi Y, Osada H, Satake H, Kojima M, Saito-Takatsuji H, Ikeda T, Yoshitake Y, Ishigaki Y, Kubo E, Sasaki H, Yonekura H.

Biol Open. 2019 Feb 18;8(2). pii: bio035691. doi: 10.1242/bio.035691.

16.

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.

Sunakawa Y, Satake H, Ichikawa W.

World J Gastrointest Oncol. 2018 Dec 15;10(12):528-531. doi: 10.4251/wjgo.v10.i12.528.

17.

Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports.

Ogata T, Kikawa Y, Ogata M, Satake H, Hatachi Y, Yasui H.

Case Rep Oncol. 2018 Oct 31;11(3):699-704. doi: 10.1159/000493848. eCollection 2018 Sep-Dec.

18.

Bilateral Xp11.2 translocation renal cell carcinoma: a case report.

Karashima T, Kuno T, Kuroda N, Satake H, Fukata S, Chikazawa M, Kawada C, Yamasaki I, Shuin T, Hiroi M, Inoue K.

BMC Urol. 2018 Nov 20;18(1):106. doi: 10.1186/s12894-018-0419-3.

19.

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.

Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H.

Intern Med. 2019 Apr 1;58(7):1029-1032. doi: 10.2169/internalmedicine.1640-18. Epub 2018 Nov 19.

20.

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.

PMID:
30391779
21.

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study.

Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, Yasui H.

Oncotarget. 2018 Oct 2;9(77):34520-34527. doi: 10.18632/oncotarget.26145. eCollection 2018 Oct 2.

22.

A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.

Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group.

Ann Surg. 2019 Aug;270(2):230-237. doi: 10.1097/SLA.0000000000002865.

PMID:
30339627
23.

Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study.

Kikawa Y, Hatachi Y, Rumpold G, Tokiwa M, Takebe S, Ogata T, Satake H, Kato H, Tsuji A, Yasui H, Holzner B.

Breast Cancer. 2019 Mar;26(2):255-259. doi: 10.1007/s12282-018-0905-1. Epub 2018 Sep 7.

24.

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.

Satake H, Sagawa T, Fujikawa K, Hatachi Y, Yasui H, Kotaka M, Kato T, Tsuji A.

Cancer Chemother Pharmacol. 2018 Nov;82(5):839-845. doi: 10.1007/s00280-018-3678-5. Epub 2018 Aug 30.

25.

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.

Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E.

Clin Colorectal Cancer. 2018 Dec;17(4):e687-e697. doi: 10.1016/j.clcc.2018.07.004. Epub 2018 Jul 29.

PMID:
30149986
26.

Lactosylceramide synthases encoded by B4galt5 and 6 genes are pivotal for neuronal generation and myelin formation in mice.

Yoshihara T, Satake H, Nishie T, Okino N, Hatta T, Otani H, Naruse C, Suzuki H, Sugihara K, Kamimura E, Tokuda N, Furukawa K, Fururkawa K, Ito M, Asano M.

PLoS Genet. 2018 Aug 16;14(8):e1007545. doi: 10.1371/journal.pgen.1007545. eCollection 2018 Aug.

27.

Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer.

Nagasaka K, Satake H, Ishigaki S, Kawai H, Naganawa S.

Breast Cancer. 2019 Jan;26(1):113-124. doi: 10.1007/s12282-018-0899-8. Epub 2018 Aug 1.

PMID:
30069785
28.

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.

Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K.

Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26.

29.

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Jul 6;9(52):30023. doi: 10.18632/oncotarget.25775. eCollection 2018 Jul 6.

30.

Long-term results after simple rotational osteotomy of the radius shaft for congenital radioulnar synostosis.

Satake H, Kanauchi Y, Kashiwa H, Ishigaki D, Takahara M, Takagi M.

J Shoulder Elbow Surg. 2018 Aug;27(8):1373-1379. doi: 10.1016/j.jse.2018.04.012.

PMID:
30016690
31.

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.

Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A.

Asia Pac J Clin Oncol. 2019 Feb;15(1):63-68. doi: 10.1111/ajco.13050. Epub 2018 Jul 8.

PMID:
29984542
32.

Elucidation of interfacial pH behaviour at the cell/substrate nanogap for in situ monitoring of cellular respiration.

Satake H, Saito A, Sakata T.

Nanoscale. 2018 May 31;10(21):10130-10136. doi: 10.1039/c8nr02950d.

PMID:
29781490
33.

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 Jul 6;9(52):30023. Ichikawa, Wararu [corrected to Ichikawa, Wataru].

34.

Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report.

Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H.

Case Rep Oncol. 2018 Mar 7;11(1):143-150. doi: 10.1159/000487477. eCollection 2018 Jan-Apr.

35.

piRNA-like small RNAs are responsible for the maternal-specific knockdown in the ascidian Ciona intestinalis Type A.

Satoh T, Iitsuka T, Shiraishi A, Hozumi A, Satake H, Sasakura Y.

Sci Rep. 2018 Apr 12;8(1):5869. doi: 10.1038/s41598-018-24319-w.

36.

Comment on Imai et al.: Manual calf massage and passive ankle motion reduce the incidence of deep vein thromboembolism after total hip arthroplasty.

Takakubo Y, Yuki H, Ito J, Oki H, Satake H, Sasaki K, Takagi M.

J Orthop Sci. 2018 May;23(3):607. doi: 10.1016/j.jos.2018.01.016. Epub 2018 Mar 12. No abstract available.

PMID:
29544723
37.

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.

Satake H, Tsuji A, Nakamura M, Ogawa M, Kotake T, Hatachi Y, Yasui H, Takagane A, Okita Y, Nakamura K, Onikubo T, Takeuchi M, Fujii M.

Int J Clin Oncol. 2018 Jun;23(3):490-496. doi: 10.1007/s10147-017-1228-5. Epub 2018 Feb 20.

38.

SHISA2 enhances the aggressive phenotype in prostate cancer through the regulation of WNT5A expression.

Tamura K, Furihata M, Satake H, Hashida H, Kawada C, Osakabe H, Fukuhara H, Kumagai N, Iiyama T, Shuin T, Inoue K.

Oncol Lett. 2017 Dec;14(6):6650-6658. doi: 10.3892/ol.2017.7099. Epub 2017 Sep 28.

39.

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).

Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T.

Cancer Chemother Pharmacol. 2018 Mar;81(3):461-468. doi: 10.1007/s00280-017-3513-4. Epub 2018 Jan 5.

PMID:
29305639
40.

Diagnosis and treatment of osteochondritis dissecans of the humeral capitellum.

Maruyama M, Takahara M, Satake H.

J Orthop Sci. 2018 Mar;23(2):213-219. doi: 10.1016/j.jos.2017.11.013. Epub 2017 Dec 22. Review.

41.

Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.

Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, Yoshioka S, Morimoto T, Ishikawa T.

Leuk Lymphoma. 2018 Sep;59(9):2144-2151. doi: 10.1080/10428194.2017.1410888. Epub 2017 Dec 18.

PMID:
29251166
42.

A Testis-Specific Long Non-Coding RNA, lncRNA-Tcam1, Regulates Immune-Related Genes in Mouse Male Germ Cells.

Kurihara M, Otsuka K, Matsubara S, Shiraishi A, Satake H, Kimura AP.

Front Endocrinol (Lausanne). 2017 Nov 2;8:299. doi: 10.3389/fendo.2017.00299. eCollection 2017.

43.

Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report.

Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H.

Case Rep Oncol. 2017 Oct 10;10(3):885-889. doi: 10.1159/000481398. eCollection 2017 Sep-Dec.

44.

Heterodimerization of the prostaglandin E2 receptor EP2 and the calcitonin receptor CTR.

Matsubara S, Shiraishi A, Sakai T, Okuda T, Satake H.

PLoS One. 2017 Nov 2;12(11):e0187711. doi: 10.1371/journal.pone.0187711. eCollection 2017.

45.

Invertebrate Gonadotropin-Releasing Hormone-Related Peptides and Their Receptors: An Update.

Sakai T, Shiraishi A, Kawada T, Matsubara S, Aoyama M, Satake H.

Front Endocrinol (Lausanne). 2017 Sep 6;8:217. doi: 10.3389/fendo.2017.00217. eCollection 2017. Review.

46.

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study.

Satake H, Yasui H, Kotake T, Okita Y, Hatachi Y, Kotaka M, Kato T, Tsuji A.

Mol Clin Oncol. 2017 Sep;7(3):347-350. doi: 10.3892/mco.2017.1335. Epub 2017 Jul 19.

47.

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.

Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y.

Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11.

48.

Comparison of the Effects of Osteochondral Autograft Transplantation With Platelet-Rich Plasma or Platelet-Rich Fibrin on Osteochondral Defects in a Rabbit Model.

Maruyama M, Satake H, Suzuki T, Honma R, Naganuma Y, Takakubo Y, Takagi M.

Am J Sports Med. 2017 Dec;45(14):3280-3288. doi: 10.1177/0363546517721188. Epub 2017 Aug 30.

PMID:
28853913
49.

Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).

Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A.

ESMO Open. 2017 Mar 9;2(1):e000130. doi: 10.1136/esmoopen-2016-000130. eCollection 2017.

50.

Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.

Satake H, Kondo M, Mizumoto M, Kotake T, Okita Y, Ogata T, Hatachi Y, Yasui H, Miki A, Imai Y, Ichikawa C, Murotani K, Kotaka M, Kato T, Kaihara S, Tsuji A.

Anticancer Res. 2017 Jul;37(7):3703-3710.

PMID:
28668863

Supplemental Content

Loading ...
Support Center